{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:18:40Z","timestamp":1793661520991,"version":"4.5.1"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40257-025-00990-4","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:42:35Z","timestamp":1761039755000},"page":"101-119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0809-4320","authenticated-orcid":false,"given":"Michael M.","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3989-8551","authenticated-orcid":false,"given":"Yingjoy","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-9304","authenticated-orcid":false,"given":"Shari R.","family":"Lipner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"1","key":"990_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12020-017-1280-y","volume":"57","author":"F Lolli","year":"2017","unstructured":"Lolli F, Pallotti F, Rossi A, et al. Androgenetic alopecia: a review. Endocrine. 2017;57(1):9\u201317. https:\/\/doi.org\/10.1007\/s12020-017-1280-y.","journal-title":"Endocrine"},{"key":"990_CR2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/CCID.S53985","volume":"8","author":"AC Villasante Fricke","year":"2015","unstructured":"Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397\u2013403. https:\/\/doi.org\/10.2147\/CCID.S53985.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"990_CR3","unstructured":"US FDA. Drug Approval Package: Rogaine NDA# 020834. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/97\/020834_rogaine_toc.cfm."},{"key":"990_CR4","unstructured":"US FDA. Loniten. Published online 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/018154s026lbl.pdf."},{"issue":"1","key":"990_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/0974-7753.82116","volume":"3","author":"P Yesudian","year":"2011","unstructured":"Yesudian P. Serendipity in trichology. Int J Trichol. 2011;3(1):1\u20132. https:\/\/doi.org\/10.4103\/0974-7753.82116.","journal-title":"Int J Trichol"},{"issue":"1","key":"990_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000534526","volume":"10","author":"N Desir","year":"2024","unstructured":"Desir N, Desai AD, Lipner SR. Increased interest in oral minoxidil for hair loss treatment following publication of August 2022 New York Times article: a Google trends analysis. Skin Appendage Disord. 2024;10(1):46\u20139. https:\/\/doi.org\/10.1159\/000534526.","journal-title":"Skin Appendage Disord"},{"key":"990_CR7","unstructured":"Kolata G. An old medicine grows new hair for pennies a day, doctors say. The New York Times. 2022. https:\/\/www.nytimes.com\/2022\/08\/18\/health\/minoxidil-hair-loss-pills.html. Accessed 4 Apr 2025."},{"issue":"3","key":"990_CR8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaad.2020.06.1009","volume":"84","author":"M Randolph","year":"2021","unstructured":"Randolph M, Tosti A. Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2021;84(3):737\u201346. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.1009.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"990_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/ijdd.ijdd_35_21","volume":"8","author":"PA Kowe","year":"2022","unstructured":"Kowe PA, Madke B, Bansod SH. Oral minoxidil in trichology: a review. Indian J Drugs Dermatol. 2022;8(1):1. https:\/\/doi.org\/10.4103\/ijdd.ijdd_35_21.","journal-title":"Indian J Drugs Dermatol"},{"key":"990_CR10","doi-asserted-by":"publisher","unstructured":"Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension | Circulation. https:\/\/doi.org\/10.1161\/01.CIR.45.3.571. Accessed 4 Apr 2025.","DOI":"10.1161\/01.CIR.45.3.571"},{"key":"990_CR11","unstructured":"Kolata G. Hair-Growth Drug Approved, The First Cleared in the U.S. The New York Times. 1988. https:\/\/www.nytimes.com\/1988\/08\/18\/us\/hair-growth-drug-approved-the-first-cleared-in-the-us.html. Accessed 4 Apr 2025."},{"issue":"5","key":"990_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/1523-1747.ep12504905","volume":"95","author":"AE Buhl","year":"1990","unstructured":"Buhl AE, Waldon DJ, Baker CA, Johnson GA. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol. 1990;95(5):553\u20137. https:\/\/doi.org\/10.1111\/1523-1747.ep12504905.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"990_CR13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1159\/000026112","volume":"8","author":"TP Dooley","year":"1999","unstructured":"Dooley TP. Molecular biology of the human cytosolic sulfotransferase gene superfamily implicated in the bioactivation of minoxidil and cholesterol in skin. Exp Dermatol. 1999;8(4):328\u20139. https:\/\/doi.org\/10.1159\/000026112.","journal-title":"Exp Dermatol"},{"key":"990_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.04.016","volume":"93","author":"EA Olsen","year":"2025","unstructured":"Olsen EA, Sinclair R, Hordinsky M, et al. Summation and recommendations for the safe and effective use of topical and oral minoxidil. J Am Acad Dermatol. 2025;93:S0190\u20139622(25)00605-X. https:\/\/doi.org\/10.1016\/j.jaad.2025.04.016.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"990_CR15","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S0022-3565(25)24105-2","volume":"245","author":"KD Meisheri","year":"1988","unstructured":"Meisheri KD, Cipkus LA, Taylor CJ. Mechanism of action of minoxidil sulfate-induced vasodilation: a role for increased K+ permeability. J Pharmacol Exp Ther. 1988;245(3):751\u201360.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1 Suppl","key":"990_CR16","doi-asserted-by":"publisher","first-page":"148S","DOI":"10.1111\/1523-1747.ep12363290","volume":"101","author":"AE Buhl","year":"1993","unstructured":"Buhl AE, Conrad SJ, Waldon DJ, Brunden MN. Potassium channel conductance as a control mechanism in hair follicles. J Invest Dermatol. 1993;101(1 Suppl):148S-152S. https:\/\/doi.org\/10.1111\/1523-1747.ep12363290.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"990_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-2133.2004.05785.x","volume":"150","author":"AG Messenger","year":"2004","unstructured":"Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186\u201394. https:\/\/doi.org\/10.1111\/j.1365-2133.2004.05785.x.","journal-title":"Br J Dermatol"},{"issue":"6","key":"990_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1159\/000531890","volume":"9","author":"AK Gupta","year":"2023","unstructured":"Gupta AK, Talukder M, Shemer A, Piraccini BM, Tosti A. Low-dose oral minoxidil for alopecia: a comprehensive review. Skin Appendage Disord. 2023;9(6):423\u201337. https:\/\/doi.org\/10.1159\/000531890.","journal-title":"Skin Appendage Disord"},{"issue":"2","key":"990_CR19","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/sj.bjp.0705613","volume":"141","author":"T Sato","year":"2004","unstructured":"Sato T, Li Y, Saito T, Nakaya H. Minoxidil opens mitochondrial KATP channels and confers cardioprotection. Br J Pharmacol. 2004;141(2):360\u20136. https:\/\/doi.org\/10.1038\/sj.bjp.0705613.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"990_CR20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2174\/187221312800166859","volume":"6","author":"A Rossi","year":"2012","unstructured":"Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6(2):130\u20136. https:\/\/doi.org\/10.2174\/187221312800166859.","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"issue":"4","key":"990_CR21","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.0022-202X.2005.23643.x","volume":"124","author":"GC Davies","year":"2005","unstructured":"Davies GC, Thornton MJ, Jenner TJ, et al. Novel and established potassium channel openers stimulate hair growth in vitro: implications for their modes of action in hair follicles. J Invest Dermatol. 2005;124(4):686\u201394. https:\/\/doi.org\/10.1111\/j.0022-202X.2005.23643.x.","journal-title":"J Invest Dermatol"},{"key":"990_CR22","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00154.2022","author":"C McClenaghan","year":"2022","unstructured":"McClenaghan C, Nichols CG. Kir6.1 and SUR2B in Cant\u00fa syndrome. Am J Physiol-Cell Physiol. 2022. https:\/\/doi.org\/10.1152\/ajpcell.00154.2022.","journal-title":"Am J Physiol-Cell Physiol"},{"issue":"1","key":"990_CR23","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.3390\/ijms15011647","volume":"15","author":"P Rishikaysh","year":"2014","unstructured":"Rishikaysh P, Dev K, Diaz D, Qureshi WMS, Filip S, Mokry J. Signaling involved in hair follicle morphogenesis and development. Int J Mol Sci. 2014;15(1):1647\u201370. https:\/\/doi.org\/10.3390\/ijms15011647.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"990_CR24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.01.013","volume":"62","author":"MH Kwack","year":"2011","unstructured":"Kwack MH, Kang BM, Kim MK, Kim JC, Sung YK. Minoxidil activates \u03b2-catenin pathway in human dermal papilla cells: a possible explanation for its anagen prolongation effect. J Dermatol Sci. 2011;62(3):154\u20139. https:\/\/doi.org\/10.1016\/j.jdermsci.2011.01.013.","journal-title":"J Dermatol Sci"},{"issue":"1","key":"990_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Xiao Q, Xiao J, et al. Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Sig Transduct Target Ther. 2022;7(1):1\u201323. https:\/\/doi.org\/10.1038\/s41392-021-00762-6.","journal-title":"Sig Transduct Target Ther."},{"issue":"3","key":"990_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1046\/j.1365-2133.1998.02115.x","volume":"138","author":"S Lachgar","year":"1998","unstructured":"Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol. 1998;138(3):407\u201311. https:\/\/doi.org\/10.1046\/j.1365-2133.1998.02115.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"990_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/1523-1747.ep12334249","volume":"108","author":"JF Michelet","year":"1997","unstructured":"Michelet JF, Commo S, Billoni N, Mah\u00e9 YF, Bernard BA. Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol. 1997;108(2):205\u20139. https:\/\/doi.org\/10.1111\/1523-1747.ep12334249.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"990_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4103\/ijt.ijt_18_17","volume":"10","author":"E Pekmezci","year":"2018","unstructured":"Pekmezci E, Turko\u011flu M, G\u00f6kalp H, Kutlubay Z. Minoxidil downregulates Interleukin-1 alpha gene expression in HaCaT cells. Int J Trichology. 2018;10(3):108. https:\/\/doi.org\/10.4103\/ijt.ijt_18_17.","journal-title":"Int J Trichology"},{"issue":"2","key":"990_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4103\/0974-7753.122963","volume":"5","author":"B Nirmal","year":"2013","unstructured":"Nirmal B, Somiah S, Sacchidanand SA, Biligi DS, Palo S. Evaluation of perifollicular inflammation of donor area during hair transplantation in androgenetic alopecia and its comparison with controls. Int J Trichology. 2013;5(2):73\u20136. https:\/\/doi.org\/10.4103\/0974-7753.122963.","journal-title":"Int J Trichology"},{"issue":"2","key":"990_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.jaad.2021.09.040","volume":"86","author":"J Plante","year":"2022","unstructured":"Plante J, Valdebran M, Forcucci J, Lucas O, Elston D. Perifollicular inflammation and follicular spongiosis in androgenetic alopecia. J Am Acad Dermatol. 2022;86(2):437\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2021.09.040.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"990_CR31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.36849\/jdd.7743","volume":"23","author":"N Ly","year":"2024","unstructured":"Ly N, McClure EM, Hordinsky MK, Farah RS, Park SY. Safety and efficacy of minoxidil treatment in scarring alopecia: a scoping review. J Drugs Dermatol. 2024;23(3):146\u201351. https:\/\/doi.org\/10.36849\/jdd.7743.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"990_CR32","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/1523-1747.ep12335779","volume":"109","author":"ME Sawaya","year":"1997","unstructured":"Sawaya ME, Price VH. Different levels of 5\u03b1-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997;109(3):296\u2013300.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"990_CR33","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1210\/jcem-38-5-811","volume":"38","author":"HU Schweikert","year":"1974","unstructured":"Schweikert HU, Wilson JD. Regulation of human hair growth by steroid hormones. I. Testosterone metabolism in isolated hairs. J Clin Endocrinol Metab. 1974;38(5):811\u20139. https:\/\/doi.org\/10.1210\/jcem-38-5-811.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"990_CR34","first-page":"703","volume":"79","author":"A Dallob","year":"1994","unstructured":"Dallob A, Sadick N, Unger W, et al. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab. 1994;79(3):703\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"990_CR35","first-page":"271","volume":"25","author":"E Pekmezci","year":"2017","unstructured":"Pekmezci E, T\u00fcrko\u011flu M. Minoxidil acts as an antiandrogen: a study of 5\u03b1-reductase type 2 gene expression in a human keratinocyte cell line. Acta Dermatovenerol Croat. 2017;25(4):271\u20135.","journal-title":"Acta Dermatovenerol Croat"},{"issue":"8","key":"990_CR36","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.18632\/oncotarget.1886","volume":"5","author":"CL Hsu","year":"2014","unstructured":"Hsu CL, Liu JS, Lin AC, Yang CH, Chung WH, Wu WG. Minoxidil may suppress androgen receptor-related functions. Oncotarget. 2014;5(8):2187\u201397.","journal-title":"Oncotarget"},{"issue":"2","key":"990_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0923-1811(98)00048-6","volume":"19","author":"T Sato","year":"1999","unstructured":"Sato T, Tadokoro T, Sonoda T, Asada Y, Itami S, Takayasu S. Minoxidil increases 17\u03b2-hydroxysteroid dehydrogenase and 5\u03b1-reductase activity of cultured human dermal papilla cells from balding scalp. J Dermatol Sci. 1999;19(2):123\u20135. https:\/\/doi.org\/10.1016\/S0923-1811(98)00048-6.","journal-title":"J Dermatol Sci"},{"issue":"3","key":"990_CR38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/1523-1747.ep12277095","volume":"92","author":"AE Buhl","year":"1989","unstructured":"Buhl AE, Waldon DJ, Kawabe TT, Holland JM. Minoxidil stimulates mouse vibrissae follicles in organ culture. J Invest Dermatol. 1989;92(3):315\u201320. https:\/\/doi.org\/10.1111\/1523-1747.ep12277095.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"990_CR39","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/1523-1747.ep12371759","volume":"102","author":"A Fratini","year":"1994","unstructured":"Fratini A, Powell BC, Hynd PI, Keough RA, Rogers GE. Dietary cysteine regulates the levels of mRNAs encoding a family of cysteine-rich proteins of wool. J Invest Dermatol. 1994;102(2):178\u201385. https:\/\/doi.org\/10.1111\/1523-1747.ep12371759.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"990_CR40","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.2527\/jas.2006-541","volume":"85","author":"N Thomas","year":"2007","unstructured":"Thomas N, Tivey DR, Penno NM, Nattrass G, Hynd PI. Characterization of transport systems for cysteine, lysine, alanine, and leucine in wool follicles of sheep. J Anim Sci. 2007;85(9):2205\u201313. https:\/\/doi.org\/10.2527\/jas.2006-541.","journal-title":"J Anim Sci"},{"issue":"Suppl 2","key":"990_CR41","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1097\/00005344-198000022-00002","volume":"2","author":"DT Lowenthal","year":"1980","unstructured":"Lowenthal DT, Affrime MB. Pharmacology and pharmacokinetics of minoxidil. J Cardiovasc Pharmacol. 1980;2(Suppl 2):S93-106. https:\/\/doi.org\/10.1097\/00005344-198000022-00002.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"990_CR42","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/0007-1226(95)90147-7","volume":"48","author":"JL Parish","year":"1995","unstructured":"Parish JL, Hughes MA, Cherry GW, Ferguson DJ. The effect of minoxidil analogues and metabolites on the contraction of collagen lattices by human skin fibroblasts. Br J Plast Surg. 1995;48(3):154\u201360. https:\/\/doi.org\/10.1016\/0007-1226(95)90147-7.","journal-title":"Br J Plast Surg"},{"issue":"8","key":"990_CR43","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/jps.2600640822","volume":"64","author":"RC Thomas","year":"1975","unstructured":"Thomas RC, Harpootlian H. Metabolism of Minoxidil, a new hypotensive agent 11: biotransformation following oral administration to rats, dogs, and monkeys. J Pharm Sci. 1975;64(8):1366\u201371. https:\/\/doi.org\/10.1002\/jps.2600640822.","journal-title":"J Pharm Sci"},{"key":"990_CR44","unstructured":"Al Aboud AM, Syed HA, Zito PM. Alopecia. In: StatPearls. StatPearls Publishing; 2025. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538178\/. Accessed 4 Apr 2025."},{"issue":"2","key":"990_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4103\/cdr.cdr_29_21","volume":"6","author":"A Kidangazhiathmana","year":"2022","unstructured":"Kidangazhiathmana A, Santhosh P. Pathogenesis of androgenetic alopecia. Clin Dermatol Rev. 2022;6(2):69. https:\/\/doi.org\/10.4103\/cdr.cdr_29_21.","journal-title":"Clin Dermatol Rev."},{"key":"990_CR46","unstructured":"Asfour L, Cranwell W, Sinclair R. Male androgenetic alopecia. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext. MDText.com, Inc.; 2000. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK278957\/. Accessed 18 Apr 2025."},{"issue":"4","key":"990_CR47","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijwd.2018.05.001","volume":"4","author":"G Fabbrocini","year":"2018","unstructured":"Fabbrocini G, Cantelli M, Masar\u00e0 A, Annunziata MC, Marasca C, Cacciapuoti S. Female pattern hair loss: a clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol. 2018;4(4):203. https:\/\/doi.org\/10.1016\/j.ijwd.2018.05.001.","journal-title":"Int J Womens Dermatol"},{"key":"990_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.04.074","author":"MM Ong","year":"2025","unstructured":"Ong MM, Avram M, McMichael A, Tosti A, Lipner SR. Antiandrogen therapy for the treatment of female pattern hair loss: a clinical review of current and emerging therapies. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.04.074.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"990_CR49","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1080\/09546634.2021.1945527","volume":"33","author":"AK Gupta","year":"2022","unstructured":"Gupta AK, Talukder M, Venkataraman M, Bamimore MA. Minoxidil: a comprehensive review. J Dermatolog Treat. 2022;33(4):1896\u2013906. https:\/\/doi.org\/10.1080\/09546634.2021.1945527.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"990_CR50","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00003495-199957010-00014","volume":"57","author":"KJ McClellan","year":"1999","unstructured":"McClellan KJ, Markham A. Finasteride: a review of its use in male pattern hair loss. Drugs. 1999;57(1):111\u201326. https:\/\/doi.org\/10.2165\/00003495-199957010-00014.","journal-title":"Drugs"},{"key":"990_CR51","doi-asserted-by":"publisher","unstructured":"Malkud S. Telogen effluvium: a review. J Clin Diagn Res. 2015;9(9):WE01\u2013WE03. https:\/\/doi.org\/10.7860\/JCDR\/2015\/15219.6492.","DOI":"10.7860\/JCDR\/2015\/15219.6492"},{"key":"990_CR52","unstructured":"Telogen effluvium\u2014UpToDate. https:\/\/www.uptodate.com\/contents\/telogen-effluvium#H1164291311. Accessed 4 June 2025."},{"issue":"5","key":"990_CR53","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1046\/j.1365-2230.2002.01080.x","volume":"27","author":"S Harrison","year":"2002","unstructured":"Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol. 2002;27(5):389\u2013385. https:\/\/doi.org\/10.1046\/j.1365-2230.2002.01080.x.","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"990_CR54","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s00403-024-02948-8","volume":"316","author":"RC Miller","year":"2024","unstructured":"Miller RC, Curtis KL, Abedian S, Lipner SR. Cost-effectiveness analysis of laboratory monitoring in newly diagnosed telogen effluvium patients. Arch Dermatol Res. 2024;316(7):388. https:\/\/doi.org\/10.1007\/s00403-024-02948-8.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"990_CR55","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jaad.2023.05.045","volume":"89","author":"RC Miller","year":"2023","unstructured":"Miller RC, Abedian S, Lipner SR. \u201cShedding\u201d low yield testing for telogen effluvium: a cross-sectional study of 16,381 laboratory results from newly diagnosed patients. J Am Acad Dermatol. 2023;89(3):623\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2023.05.045.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"990_CR56","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jaad.2022.04.030","volume":"87","author":"B de Nicolas-Ruanes","year":"2022","unstructured":"de Nicolas-Ruanes B, Moreno-Arrones OM, Saceda-Corralo D, et al. Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: a descriptive study. J Am Acad Dermatol. 2022;87(3):700\u20132. https:\/\/doi.org\/10.1016\/j.jaad.2022.04.030.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"990_CR57","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00403-022-02331-5","volume":"315","author":"B Feaster","year":"2023","unstructured":"Feaster B, Onamusi T, Cooley JE, McMichael AJ. Oral minoxidil use in androgenetic alopecia and telogen effluvium. Arch Dermatol Res. 2023;315(2):201\u20135. https:\/\/doi.org\/10.1007\/s00403-022-02331-5.","journal-title":"Arch Dermatol Res"},{"key":"990_CR58","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.12688\/f1000research.11775.1","volume":"6","author":"E Perera","year":"2017","unstructured":"Perera E, Sinclair R. Treatment of chronic telogen effluvium with oral minoxidil: a retrospective study. F1000Res. 2017;6:1650. https:\/\/doi.org\/10.12688\/f1000research.11775.1.","journal-title":"F1000Res"},{"issue":"3","key":"990_CR59","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/12034754231168839","volume":"27","author":"C Sibbald","year":"2023","unstructured":"Sibbald C. Alopecia areata: an updated review for 2023. J Cutan Med Surg. 2023;27(3):241\u201359. https:\/\/doi.org\/10.1177\/12034754231168839.","journal-title":"J Cutan Med Surg"},{"key":"990_CR60","unstructured":"Messenger A. Alopecia areata: management\u2014UpToDate. https:\/\/www.uptodate.com\/contents\/alopecia-areata-management#H37."},{"issue":"5","key":"990_CR61","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/j.1365-2133.2012.10955.x","volume":"166","author":"AG Messenger","year":"2012","unstructured":"Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British association of dermatologists\u2019 guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166(5):916\u201326. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10955.x.","journal-title":"Br J Dermatol"},{"issue":"6","key":"990_CR62","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaad.2021.04.077","volume":"86","author":"VR Barton","year":"2022","unstructured":"Barton VR, Toussi A, Awasthi S, Kiuru M. Treatment of pediatric alopecia areata: a systematic review. J Am Acad Dermatol. 2022;86(6):1318\u201334. https:\/\/doi.org\/10.1016\/j.jaad.2021.04.077.","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"990_CR63","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2110343.","journal-title":"N Engl J Med"},{"issue":"4","key":"990_CR64","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/jdv.19768","volume":"38","author":"L Rudnicka","year":"2024","unstructured":"Rudnicka L, Arenbergerova M, Grimalt R, et al. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2024;38(4):687\u201394. https:\/\/doi.org\/10.1111\/jdv.19768.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"990_CR65","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1001\/archderm.1987.01660350088019","volume":"123","author":"VC Fiedler-Weiss","year":"1987","unstructured":"Fiedler-Weiss VC, Rumsfield J, Buys CM, West DP, Wendrow A. Evaluation of oral minoxidil in the treatment of alopecia areata. Arch Dermatol. 1987;123(11):1488\u201390.","journal-title":"Arch Dermatol"},{"issue":"5","key":"990_CR66","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.jaad.2022.12.033","volume":"88","author":"A Moussa","year":"2023","unstructured":"Moussa A, Eisman S, Kazmi A, et al. Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: a retrospective review of 29 patients. J Am Acad Dermatol. 2023;88(5):1194\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.033.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"990_CR67","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/ijd.14933","volume":"59","author":"AN Sharma","year":"2020","unstructured":"Sharma AN, Michelle L, Juhasz M, Muller Ramos P, Atanaskova Mesinkovska N. Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. Int J Dermatol. 2020;59(8):1013\u20139. https:\/\/doi.org\/10.1111\/ijd.14933.","journal-title":"Int J Dermatol"},{"issue":"7","key":"990_CR68","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1111\/jdv.17216","volume":"35","author":"A Villani","year":"2021","unstructured":"Villani A, Fabbrocini G, Ocampo-Candiani J, Ruggiero A, Ocampo-Garza SS. Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose. J Eur Acad Dermatol Venereol. 2021;35(7):1485\u201392. https:\/\/doi.org\/10.1111\/jdv.17216.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"990_CR69","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jaad.2019.08.080","volume":"85","author":"CG Wambier","year":"2021","unstructured":"Wambier CG, Craiglow BG, King BA. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. J Am Acad Dermatol. 2021;85(3):743\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.080.","journal-title":"J Am Acad Dermatol"},{"key":"990_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.05.1446","author":"L Kalil","year":"2025","unstructured":"Kalil L, Valido K, Peterson D, King B. Oral minoxidil treatment of Alopecia Areata. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1446.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"990_CR71","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.2353\/ajpath.2010.100454","volume":"177","author":"MJ Harries","year":"2010","unstructured":"Harries MJ, Paus R. The pathogenesis of primary cicatricial alopecias. Am J Pathol. 2010;177(5):2152\u201362. https:\/\/doi.org\/10.2353\/ajpath.2010.100454.","journal-title":"Am J Pathol"},{"issue":"18","key":"990_CR72","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1503\/cmaj.111570","volume":"185","author":"R Filbrandt","year":"2013","unstructured":"Filbrandt R, Rufaut N, Jones L, Sinclair R. Primary cicatricial alopecia: diagnosis and treatment. CMAJ. 2013;185(18):1579\u201385. https:\/\/doi.org\/10.1503\/cmaj.111570.","journal-title":"CMAJ"},{"key":"990_CR73","doi-asserted-by":"publisher","unstructured":"Variant PADI3 in Central Centrifugal Cicatricial Alopecia | New England Journal of Medicine. https:\/\/doi.org\/10.1056\/NEJMoa1816614. Accessed 4 June 2025.","DOI":"10.1056\/NEJMoa1816614"},{"key":"990_CR74","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jdcr.2022.07.038","volume":"28","author":"M Karim","year":"2022","unstructured":"Karim M, Klein EJ, Brinster N, Rieder E, Lo Sicco K, Shapiro J. Reversible hair loss in a patient with cicatricial alopecia: a case of regrowth associated with pioglitazone use. JAAD Case Rep. 2022;28:21\u20133. https:\/\/doi.org\/10.1016\/j.jdcr.2022.07.038.","journal-title":"JAAD Case Rep"},{"key":"990_CR75","unstructured":"Agbai O. Frontal fibrosing alopecia: management\u2014UpToDate. https:\/\/www.uptodate.com\/contents\/frontal-fibrosing-alopecia-management#H2418202906."},{"key":"990_CR76","unstructured":"Aguh C. Central centrifugal cicatricial alopecia\u2014UpToDate. https:\/\/www.uptodate.com\/contents\/central-centrifugal-cicatricial-alopecia#H12560801."},{"issue":"3","key":"990_CR77","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10549-024-07440-5","volume":"208","author":"AMS Kuo","year":"2024","unstructured":"Kuo AMS, Reingold RE, Ketosugbo KF, et al. Oral minoxidil for late alopecia in cancer survivors. Breast Cancer Res Treat. 2024;208(3):491\u20139. https:\/\/doi.org\/10.1007\/s10549-024-07440-5.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"990_CR78","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/pon.4039","volume":"26","author":"P Dua","year":"2017","unstructured":"Dua P, Heiland MF, Kracen AC, Deshields TL. Cancer-related hair loss: a selective review of the alopecia research literature. Psychooncology. 2017;26(4):438\u201343. https:\/\/doi.org\/10.1002\/pon.4039.","journal-title":"Psychooncology"},{"issue":"5","key":"990_CR79","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jaad.2018.03.055","volume":"80","author":"A Freites-Martinez","year":"2019","unstructured":"Freites-Martinez A, Shapiro J, Goldfarb S, et al. Hair disorders in patients with cancer. J Am Acad Dermatol. 2019;80(5):1179\u201396. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.055.","journal-title":"J Am Acad Dermatol"},{"issue":"26","key":"990_CR80","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1200\/JCO.23.02374","volume":"42","author":"D Kang","year":"2024","unstructured":"Kang D, Cho J, Zhao D, et al. Scalp cooling in preventing persistent chemotherapy-induced alopecia: a randomized controlled trial. J Clin Oncol. 2024;42(26):3115\u201322. https:\/\/doi.org\/10.1200\/JCO.23.02374.","journal-title":"J Clin Oncol"},{"issue":"5","key":"990_CR81","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jaad.2022.12.005","volume":"88","author":"J Kang","year":"2023","unstructured":"Kang J, Lee JW, Kwon O. Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: a retrospective cohort study. J Am Acad Dermatol. 2023;88(5):1170\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.005.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"990_CR82","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1303a152","volume":"13","author":"M Iorizzo","year":"2023","unstructured":"Iorizzo M, Wa\u015bkiel-Burnat A, Anedda J, et al. Persistent chemotherapy-induced alopecia treated with low dose oral minoxidil: a multicenter retrospective case series of 15 patients. Dermatol Pract Concept. 2023;13(3):e2023152. https:\/\/doi.org\/10.5826\/dpc.1303a152.","journal-title":"Dermatol Pract Concept."},{"issue":"6","key":"990_CR83","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1159\/000525463","volume":"8","author":"F Martora","year":"2022","unstructured":"Martora F, Vastarella M, Fattore D, Patri A, Fabbrocini G, Cantelli M. Oral minoxidil for chemotherapy-induced alopecia. Skin Appendage Disord. 2022;8(6):508\u201310. https:\/\/doi.org\/10.1159\/000525463.","journal-title":"Skin Appendage Disord"},{"issue":"3","key":"990_CR84","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1003a74","volume":"10","author":"A Rossi","year":"2020","unstructured":"Rossi A, Caro G, Fortuna MC, Pigliacelli F, D\u2019Arino A, Carlesimo M. Prevention and treatment of chemotherapy-induced alopecia. Dermatol Pract Concept. 2020;10(3):e2020074. https:\/\/doi.org\/10.5826\/dpc.1003a74.","journal-title":"Dermatol Pract Concept."},{"key":"990_CR85","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70021","author":"A Freites-Martinez","year":"2025","unstructured":"Freites-Martinez A, Apalla Z, Shapiro J, et al. Expert consensus for prevention, diagnosis and management of persistent chemotherapy-induced alopecia. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.70021.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"990_CR86","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/ijd.17524","volume":"64","author":"MVS Sobral","year":"2025","unstructured":"Sobral MVS, Moreira JLML, Rodrigues LK, et al. Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta-analysis of randomized clinical trials. Int J Dermatol. 2025;64(3):479\u201384. https:\/\/doi.org\/10.1111\/ijd.17524.","journal-title":"Int J Dermatol"},{"issue":"6","key":"990_CR87","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1001\/jamadermatol.2024.0284","volume":"160","author":"MA Penha","year":"2024","unstructured":"Penha MA, Miot HA, Kasprzak M, M\u00fcller Ramos P. Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol. 2024;160(6):600\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2024.0284.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"990_CR88","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1111\/jocd.16362","volume":"23","author":"AK Gupta","year":"2024","unstructured":"Gupta AK, Bamimore MA, Wang T, Talukder M. The impact of monotherapies for male androgenetic alopecia: a network meta-analysis study. J Cosmet Dermatol. 2024;23(9):2964\u201372. https:\/\/doi.org\/10.1111\/jocd.16362.","journal-title":"J Cosmet Dermatol"},{"key":"990_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.09.031","author":"LPC Fonseca","year":"2025","unstructured":"Fonseca LPC, Miot HA, Chaves CRP, Ramos PM. Oral minoxidil 2.5 mg vs 5 mg for male androgenetic alopecia: a double-blind randomized clinical trial. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.09.031.","journal-title":"J Am Acad Dermatol"},{"key":"990_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.017","author":"P Jean-Pierre","year":"2024","unstructured":"Jean-Pierre P, Williams KN. Direct-to-consumer androgenetic alopecia treatments: a cost comparison with traditional pharmacies. J Am Acad Dermatol. 2024. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.017.","journal-title":"J Am Acad Dermatol"},{"key":"990_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.02.089","author":"M Ranpariya","year":"2025","unstructured":"Ranpariya M, Lipoff JB. Discount pharmacies may save patients significant money on androgenetic alopecia medications compared to both traditional pharmacies and direct-to-consumer companies. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.02.089.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"990_CR92","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jaad.2024.12.005","volume":"92","author":"MM Ong","year":"2025","unstructured":"Ong MM, Lipner SR. Evaluating safety and ethical implications of androgenetic alopecia treatments: a comparison of direct-to-consumer platforms and dermatologist visits. J Am Acad Dermatol. 2025;92(4):960\u20131. https:\/\/doi.org\/10.1016\/j.jaad.2024.12.005.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"990_CR93","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1046\/j.1365-2133.1999.03030.x","volume":"141","author":"TF Cash","year":"1999","unstructured":"Cash TF. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol. 1999;141(3):398\u2013405. https:\/\/doi.org\/10.1046\/j.1365-2133.1999.03030.x.","journal-title":"Br J Dermatol"},{"issue":"5","key":"990_CR94","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s13555-023-00919-x","volume":"13","author":"Z Shadi","year":"2023","unstructured":"Shadi Z. Compliance to topical minoxidil and reasons for discontinuation among patients with androgenetic alopecia. Dermatol Ther (Heidelb). 2023;13(5):1157\u201369. https:\/\/doi.org\/10.1007\/s13555-023-00919-x.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"990_CR95","doi-asserted-by":"publisher","first-page":"131","DOI":"10.36849\/JDD.8424","volume":"24","author":"S Kobayashi","year":"2025","unstructured":"Kobayashi S, Rose L, Minta A, Trovato S, Dulmage B. Comparing adherence, side effects, and satisfaction in oral and topical minoxidil: a cross-sectional study. J Drugs Dermatol. 2025;24(2):131\u20133. https:\/\/doi.org\/10.36849\/JDD.8424.","journal-title":"J Drugs Dermatol"},{"key":"990_CR96","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14106","author":"J Jimenez-Cauhe","year":"2020","unstructured":"Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, et al. Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data. Dermatol Ther. 2020. https:\/\/doi.org\/10.1111\/dth.14106.","journal-title":"Dermatol Ther"},{"key":"990_CR97","doi-asserted-by":"publisher","DOI":"10.1159\/000542630","author":"MM Ong","year":"2024","unstructured":"Ong MM, Do H, Ho B, Lipner SR. Gender differences in adverse effects and dosing practices of low-dose oral minoxidil for androgenetic alopecia: a retrospective analysis of 310 patients. Skin Appendage Disord. 2024. https:\/\/doi.org\/10.1159\/000542630.","journal-title":"Skin Appendage Disord"},{"issue":"6","key":"990_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14061805","volume":"14","author":"J Jimenez-Cauhe","year":"2025","unstructured":"Jimenez-Cauhe J, Lo Sicco KI, Shapiro J, et al. Characterization and management of adverse events of low-dose oral minoxidil treatment for alopecia: a narrative review. J Clin Med. 2025;14(6):1805. https:\/\/doi.org\/10.3390\/jcm14061805.","journal-title":"J Clin Med"},{"key":"990_CR99","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jdrv.2025.02.013","volume":"4","author":"M Weichert","year":"2025","unstructured":"Weichert M, Chen M, Guo W, Schrock N, Briley J. Efficacy and safety of minoxidil therapy: a systematic review and meta-analysis weighing the benefits against the risk of hypertrichosis. JAAD Rev. 2025;4:58\u201360. https:\/\/doi.org\/10.1016\/j.jdrv.2025.02.013.","journal-title":"JAAD Rev."},{"key":"990_CR100","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jdrv.2024.08.002","volume":"2","author":"DD Desai","year":"2024","unstructured":"Desai DD, Nohria A, Brinks A, Needle C, Shapiro J, Lo Sicco KI. Minoxidil-induced hypertrichosis: pathophysiology, clinical implications, and therapeutic strategies. JAAD Rev. 2024;2:41\u20139. https:\/\/doi.org\/10.1016\/j.jdrv.2024.08.002.","journal-title":"JAAD Rev"},{"issue":"8","key":"990_CR101","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00403-024-03261-0","volume":"316","author":"A Nohria","year":"2024","unstructured":"Nohria A, Desai D, Sikora M, et al. To evaluate hypertrichosis with low dose oral minoxidil and spironolactone combination therapy for alopecia. Arch Dermatol Res. 2024;316(8):510. https:\/\/doi.org\/10.1007\/s00403-024-03261-0.","journal-title":"Arch Dermatol Res"},{"key":"990_CR102","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70060","author":"J Jimenez-Cauhe","year":"2025","unstructured":"Jimenez-Cauhe J, Gil-Redondo R, Saceda-Corralo D, et al. Spironolactone and bicalutamide selectively reduce facial hypertrichosis induced by low-dose oral minoxidil. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.70060.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"990_CR103","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2480739","volume":"36","author":"L Bi","year":"2025","unstructured":"Bi L, Kan H, Wang J, et al. Whether the transient hair shedding phase exist after minoxidil treatment and does it predict treatment efficacy? A retrospective study in androgenetic alopecia patients. J Dermatolog Treat. 2025;36(1):2480739. https:\/\/doi.org\/10.1080\/09546634.2025.2480739.","journal-title":"J Dermatolog Treat"},{"key":"990_CR104","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jdin.2024.03.005","volume":"15","author":"A Nohria","year":"2024","unstructured":"Nohria A, Desai D, Sikora M, Mandal S, Shapiro J, Sicco KL. Combating \u201cdread shed\u201d: the impact of overlapping topical and oral minoxidil on temporary hair shedding during oral minoxidil initiation. JAAD International. 2024;15:220\u20134. https:\/\/doi.org\/10.1016\/j.jdin.2024.03.005.","journal-title":"JAAD International."},{"issue":"1 Suppl","key":"990_CR105","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1016\/j.ijwd.2017.02.016","volume":"3","author":"S Saed","year":"2017","unstructured":"Saed S, Ibrahim O, Bergfeld WF. Hair camouflage: a comprehensive review. Int J Womens Dermatol. 2017;3(1 Suppl):S75\u201380. https:\/\/doi.org\/10.1016\/j.ijwd.2017.02.016.","journal-title":"Int J Womens Dermatol"},{"issue":"6","key":"990_CR106","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/j.jaad.2024.12.048","volume":"92","author":"J Jimenez-Cauhe","year":"2025","unstructured":"Jimenez-Cauhe J, Gil-Redondo R, Saceda-Corralo D, et al. Spironolactone reduces the risk of low-dose oral minoxidil-induced edema in women with female pattern hair loss. J Am Acad Dermatol. 2025;92(6):e197\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2024.12.048.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"990_CR107","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jaad.2024.09.078","volume":"92","author":"J Salas","year":"2025","unstructured":"Salas J, Esse I, Kincaid CM, Birda A, Choe S, Mesinkovska NA. Characterizing low-dose oral minoxidil-induced peripheral edema in alopecia patients. J Am Acad Dermatol. 2025;92(3):632\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.078.","journal-title":"J Am Acad Dermatol"},{"key":"990_CR108","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jdin.2025.05.010","volume":"22","author":"D Desai","year":"2025","unstructured":"Desai D, Nohria A, Brinks A, et al. Impact of underlying medical conditions and medications on edema development in alopecia patients treated with low-dose oral minoxidil: a retrospective study. JAAD International. 2025;22:32\u20134. https:\/\/doi.org\/10.1016\/j.jdin.2025.05.010.","journal-title":"JAAD International"},{"issue":"5","key":"990_CR109","doi-asserted-by":"publisher","first-page":"T460","DOI":"10.1016\/j.ad.2023.04.003","volume":"114","author":"JF Mir-Bonaf\u00e9","year":"2023","unstructured":"Mir-Bonaf\u00e9 JF, Mir-Bonaf\u00e9 M, Rozas-Mu\u00f1oz E, Mir-Bonaf\u00e9 JM. [Translated article] morning periorbital edema related to low-dose oral minoxidil. Actas Dermosifiliogr. 2023;114(5):T460\u20131. https:\/\/doi.org\/10.1016\/j.ad.2023.04.003.","journal-title":"Actas Dermosifiliogr"},{"key":"990_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.07.065","author":"ZJK Neubauer","year":"2025","unstructured":"Neubauer ZJK, Lipner HI, Lipner SR. No association between low-dose oral minoxidil and tachycardia in a large retrospective cohort study of patients with non-scarring alopecia. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.07.065.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"990_CR111","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jaad.2022.05.026","volume":"88","author":"BD Sanabria","year":"2023","unstructured":"Sanabria BD, Palmegiani E, Seron AF, Perdomo YC, Miot HA, M\u00fcller Ramos P. Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2023;88(2):436\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2022.05.026.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"990_CR112","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ad.2023.07.019","volume":"115","author":"J Jimenez-Cauhe","year":"2024","unstructured":"Jimenez-Cauhe J, Pirmez R, M\u00fcller-Ramos P, et al. Safety of low-dose oral minoxidil in patients with hypertension and arrhythmia: a multicenter study of 264 patients. Actas Dermosifiliogr. 2024;115(1):28\u201335. https:\/\/doi.org\/10.1016\/j.ad.2023.07.019.","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"990_CR113","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1001\/jamadermatol.2024.4593","volume":"161","author":"YM Akiska","year":"2025","unstructured":"Akiska YM, Mirmirani P, Roseborough I, et al. Low-dose oral minoxidil initiation for patients with hair loss: an international modified delphi consensus statement. JAMA Dermatol. 2025;161(1):87\u201395. https:\/\/doi.org\/10.1001\/jamadermatol.2024.4593.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"990_CR114","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jaad.2024.10.057","volume":"92","author":"M Chen","year":"2025","unstructured":"Chen M, Weichert M, Guo W, Ruzic R, Briley J. Low-dose oral minoxidil does not significantly affect blood pressure: a systematic review and meta-analysis. J Am Acad Dermatol. 2025;92(3):554\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2024.10.057.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"990_CR115","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1016\/j.jaad.2022.06.1205","volume":"87","author":"J Jimenez-Cauhe","year":"2022","unstructured":"Jimenez-Cauhe J, Saceda-Corralo D, Hermosa-Gelbard A, et al. Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil. J Am Acad Dermatol. 2022;87(6):e235\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2022.06.1205.","journal-title":"J Am Acad Dermatol"},{"key":"990_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.12.053","author":"R Chan","year":"2025","unstructured":"Chan R, Ong MM, Neubauer Z, Lipner SR. Low-dose oral minoxidil for androgenetic alopecia is not associated with blood pressure changes in patients also taking other antihypertensive medications: a multicenter cohort study using TriNetX. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2024.12.053.","journal-title":"J Am Acad Dermatol"},{"key":"990_CR117","doi-asserted-by":"crossref","unstructured":"Ong MM, Lipner SR. Orthostatic symptoms in women treated with low-dose oral minoxidil in the absence of overt hypotension: implications for clinical practice. J Am Acad Dermatol. 2025.","DOI":"10.1016\/j.jaad.2025.06.056"},{"key":"990_CR118","doi-asserted-by":"crossref","unstructured":"Ong M, Lipner SR. Low-dose oral minoxidil for treatment of androgenetic alopecia: gender differences in blood pressure and hypotension-related adverse effects. Response to Desai et al., \u201cResponse to \u2018Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: a retrospective study.\u2019\u201d J Am Acad Dermatol. 2024.","DOI":"10.1016\/j.jaad.2024.02.055"},{"issue":"1","key":"990_CR119","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/clpt.1981.128","volume":"30","author":"MJ Reichgott","year":"1981","unstructured":"Reichgott MJ. Minoxidil and pericardial effusion: an idiosyncratic reaction. Clin Pharmacol Ther. 1981;30(1):64\u201370. https:\/\/doi.org\/10.1038\/clpt.1981.128.","journal-title":"Clin Pharmacol Ther"},{"key":"990_CR120","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jdcr.2022.08.057","volume":"29","author":"K Bentivegna","year":"2022","unstructured":"Bentivegna K, Zhou AE, Adalsteinsson JA, Sloan B. Letter in reply: Pericarditis and peripheral edema in a healthy man on low-dose oral minoxidil therapy. JAAD Case Rep. 2022;29:110\u20131. https:\/\/doi.org\/10.1016\/j.jdcr.2022.08.057.","journal-title":"JAAD Case Rep"},{"key":"990_CR121","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jdcr.2022.07.044","volume":"28","author":"NC Dlova","year":"2022","unstructured":"Dlova NC, Jacobs T, Singh S. Pericardial, pleural effusion and anasarca: a rare complication of low-dose oral minoxidil for hair loss. JAAD Case Rep. 2022;28:94\u20136. https:\/\/doi.org\/10.1016\/j.jdcr.2022.07.044.","journal-title":"JAAD Case Rep"},{"key":"990_CR122","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jdcr.2022.09.035","volume":"30","author":"RM Tr\u00fceb","year":"2022","unstructured":"Tr\u00fceb RM, Caballero-Uribe N, Luu NNC, Dmitriev A. Serious complication of low-dose oral minoxidil for hair loss. JAAD Case Rep. 2022;30:97\u20138. https:\/\/doi.org\/10.1016\/j.jdcr.2022.09.035.","journal-title":"JAAD Case Rep"},{"issue":"1","key":"990_CR123","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.16574","volume":"24","author":"AK Gupta","year":"2025","unstructured":"Gupta AK, Bamimore MA, Abdel-Qadir H, et al. Low-dose oral minoxidil and associated adverse events: analyses of the FDA adverse event reporting system (FAERS) with a focus on pericardial effusions. J Cosmet Dermatol. 2025;24(1):e16574. https:\/\/doi.org\/10.1111\/jocd.16574.","journal-title":"J Cosmet Dermatol"},{"issue":"9","key":"990_CR124","doi-asserted-by":"publisher","first-page":"725","DOI":"10.36849\/JDD.8029","volume":"23","author":"CM Kincaid","year":"2024","unstructured":"Kincaid CM, Sharma AN, Sargent B, Gradus-Pizlo I, Dineen EH, Mesinkovska NA. Evaluation of pericardial effusions in alopecia patients on low-dose oral minoxidil therapy. J Drugs Dermatol. 2024;23(9):725\u20138. https:\/\/doi.org\/10.36849\/JDD.8029.","journal-title":"J Drugs Dermatol"},{"key":"990_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.08.079","author":"CJ Thang","year":"2025","unstructured":"Thang CJ, Levine J, Mo L, et al. Cardiovascular safety of low-dose oral minoxidil in nonscarring alopecia: a multicenter population-based cohort study using TriNetX. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.08.079.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"990_CR126","first-page":"91","volume":"20","author":"EC Callen","year":"2007","unstructured":"Callen EC, Church CO, Hernandez CL, Thompson ED. Stevens-Johnson syndrome associated with oral minoxidil: a case report. J Nephrol. 2007;20(1):91\u20133.","journal-title":"J Nephrol"},{"issue":"4","key":"990_CR127","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1592\/phco.29.4.460","volume":"29","author":"LR Karaoui","year":"2009","unstructured":"Karaoui LR, Chahine-Chakhtoura C. Fatal toxic epidermal necrolysis associated with minoxidil. Pharmacotherapy. 2009;29(4):460\u20137. https:\/\/doi.org\/10.1592\/phco.29.4.460.","journal-title":"Pharmacotherapy"},{"issue":"11","key":"990_CR128","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1001\/archinte.1981.00340120123025","volume":"141","author":"DJ DiSantis","year":"1981","unstructured":"DiSantis DJ, Flanagan J. Minoxidil-induced Stevens-Johnson syndrome. Arch Intern Med. 1981;141(11):1515. https:\/\/doi.org\/10.1001\/archinte.1981.00340120123025.","journal-title":"Arch Intern Med"},{"issue":"12","key":"990_CR129","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1001\/archinte.1978.03630370064027","volume":"138","author":"T Rosenthal","year":"1978","unstructured":"Rosenthal T, Teicher A, Swartz J, Boichis H. Minoxidil-induced bullous eruption. Arch Intern Med. 1978;138(12):1856\u20137.","journal-title":"Arch Intern Med"},{"issue":"7","key":"990_CR130","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s13555-024-01197-x","volume":"14","author":"KN Williams","year":"2024","unstructured":"Williams KN, Olukoga CTY, Tosti A. Evaluation of the safety and effectiveness of oral minoxidil in children: a systematic review. Dermatol Ther (Heidelb). 2024;14(7):1709\u201327. https:\/\/doi.org\/10.1007\/s13555-024-01197-x.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"990_CR131","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/ijd.16373","volume":"62","author":"JM John","year":"2023","unstructured":"John JM, Sinclair RD. Systemic minoxidil for hair disorders in pediatric patients: a safety and tolerability review. Int J Dermatol. 2023;62(2):257\u20139. https:\/\/doi.org\/10.1111\/ijd.16373.","journal-title":"Int J Dermatol"},{"issue":"2","key":"990_CR132","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jaad.2022.06.1195","volume":"88","author":"JM John","year":"2023","unstructured":"John JM, Sinclair R. Safety and tolerability of low-dose oral minoxidil in adolescents: a retrospective review. J Am Acad Dermatol. 2023;88(2):502\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2022.06.1195.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"990_CR133","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jaad.2021.08.067","volume":"89","author":"JL Gao","year":"2023","unstructured":"Gao JL, Streed CG, Thompson J, Dommasch ED, Peebles JK. Androgenetic alopecia in transgender and gender diverse populations: a review of therapeutics. J Am Acad Dermatol. 2023;89(4):774\u201383. https:\/\/doi.org\/10.1016\/j.jaad.2021.08.067.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"990_CR134","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40257-018-0343-z","volume":"19","author":"Y Gao","year":"2018","unstructured":"Gao Y, Maurer T, Mirmirani P. Understanding and addressing hair disorders in transgender individuals. Am J Clin Dermatol. 2018;19(4):517\u201327. https:\/\/doi.org\/10.1007\/s40257-018-0343-z.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"990_CR135","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1529-8019.2008.00214.x","volume":"21","author":"VA Randall","year":"2008","unstructured":"Randall VA. Androgens and hair growth. Dermatol Ther. 2008;21(5):314\u201328. https:\/\/doi.org\/10.1111\/j.1529-8019.2008.00214.x.","journal-title":"Dermatol Ther"},{"key":"990_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.06.029","author":"D Zaminski","year":"2025","unstructured":"Zaminski D, Zampella J, Shapiro J, Lo Sicco KI, Mazori DR. Use of low-dose oral minoxidil for hair growth in transgender and gender non-binary adult patients: a retrospective cohort study. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.06.029.","journal-title":"J Am Acad Dermatol"},{"key":"990_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.08.061","author":"D Ramos-Rodr\u00edguez","year":"2025","unstructured":"Ramos-Rodr\u00edguez D, Sanchez-Baez D, Garcia PC, et al. Use of oral minoxidil for androgenetic alopecia in transgender and gender-diverse people. A retrospective study of 27 patients. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.08.061.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"990_CR138","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/bdra.10095","volume":"67","author":"C Smorlesi","year":"2003","unstructured":"Smorlesi C, Caldarella A, Caramelli L, Di Lollo S, Moroni F. Topically applied minoxidil may cause fetal malformation: a case report. Birth Defects Res A Clin Mol Teratol. 2003;67(12):997\u20131001. https:\/\/doi.org\/10.1002\/bdra.10095.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"3","key":"990_CR139","doi-asserted-by":"publisher","first-page":"e224","DOI":"10.1111\/jdv.17755","volume":"36","author":"RM Tr\u00fceb","year":"2022","unstructured":"Tr\u00fceb RM, Caballero-Uribe N. Minoxidil-induced hypertrichosis in a breastfed infant. J Eur Acad Dermatol Venereol. 2022;36(3):e224\u20135. https:\/\/doi.org\/10.1111\/jdv.17755.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"990_CR140","doi-asserted-by":"publisher","first-page":"135","DOI":"10.7326\/0003-4819-102-1-135_1","volume":"102","author":"A Valdivieso","year":"1985","unstructured":"Valdivieso A, Vald\u00e9s G, Spiro TE, Westerman RL. Minoxidil in breast milk. Ann Intern Med. 1985;102(1):135\u2013135. https:\/\/doi.org\/10.7326\/0003-4819-102-1-135_1.","journal-title":"Ann Intern Med"},{"key":"990_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.05.1363","author":"J Jimenez-Cauhe","year":"2025","unstructured":"Jimenez-Cauhe J, Gonz\u00e1lez-Ramos M, Imbernon-Moya A, et al. Safety and tolerability of low-dose oral minoxidil in patients aged 65 or older: a multicenter study of 321 patients. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1363.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"990_CR142","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0190-9622(99)70006-X","volume":"41","author":"VH Price","year":"1999","unstructured":"Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol. 1999;41(5):717\u201321. https:\/\/doi.org\/10.1016\/S0190-9622(99)70006-X.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"990_CR143","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/j.jaad.2020.04.026","volume":"84","author":"S Va\u00f1\u00f3-Galv\u00e1n","year":"2021","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, de Carvalho LT, Saceda-Corralo D, et al. Oral minoxidil improves background hair thickness in lichen planopilaris. J Am Acad Dermatol. 2021;84(6):1684\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.026.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"990_CR144","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1111\/jdv.18489","volume":"37","author":"G Gallo","year":"2023","unstructured":"Gallo G, Burzi L, Torrelli F, Quaglino P, Ribero S. Low-dose oral minoxidil in female patients with lichen planopilaris: real-life experience. J Eur Acad Dermatol Venereol. 2023;37(1):e98\u2013100. https:\/\/doi.org\/10.1111\/jdv.18489.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"990_CR145","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jaad.2020.10.032","volume":"84","author":"RA Beach","year":"2021","unstructured":"Beach RA, McDonald KA, Muylaert Barrett B. Low-dose oral minoxidil for treating alopecia: a 3-year North American retrospective case series. J Am Acad Dermatol. 2021;84(3):761\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2020.10.032.","journal-title":"J Am Acad Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00990-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00990-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00990-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:51:03Z","timestamp":1769849463000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00990-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":145,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["990"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00990-4","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflict of interest. Dr Shari Lipner has served as a consultant for Moberg Pharmaceuticals and BelleTorus Corporation. Michael M. Ong and Yingjoy Li have no financial disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No datasets were generated or analyzed for this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Conceptualization: Shari R. Lipner; Literature search: Michael M. Ong, Yingjoy Li; Visualization: Yingjoy Li; Writing\u2014original draft preparation: Michael M. Ong; Writing\u2014Review and Editing: Yingjoy Li, Shari R. Lipner.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}